Previous 10 | Next 10 |
Inhibrx press release ( NASDAQ: INBX ): Q3 GAAP EPS of -$0.90 beats by $0.04 . Revenue of $0.28M (-88.9% Y/Y) misses by $0.29M . For further details see: Inhibrx GAAP EPS of -$0.90 beats by $0.04, revenue of $0.28M misses by $0.29M
Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong eme...
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire SAN DIEGO , Oct. 20, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and...
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatmen...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx (NASDAQ: INBX ) finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with the Food and Drug A...
Inhibrx ( NASDAQ: INBX ) stock rose ~33% on Oct. 4 after the company said there was potential to pursue an accelerated approval in the U.S. for INBRX-101 to treat a lung disorder, after discussions with the U.S. Food and Drug Administration (FDA). The company is...
Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study PR Newswire SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- In...
Inhibrx ( NASDAQ: INBX ) shares fell 8% in after-hours trading Monday after announcing it will hold a webcast on Tuesday morning to discuss the regulatory pathway for INBRX-101 for alpha-1 antitrypsin deficiency (AATD) . AATD is an orphan disease affecting ~100...
Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire – Event to be webcast live on Tuesday, October 4, 2022 at 5:30 a.m. PT ...
Inhibrx ( NASDAQ: INBX ) on Monday said the European Commission had granted an orphan drug designation to the biotech's antibody INBRX-109 for the treatment of chondrosarcoma, a type of bonce cancer. The European Commission's approval was based on a positive recommendation...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...